Jefferies reiterated its Buy rating and $13 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following the presentation phase III parkinson's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE